Remove Biopharma Remove Pharma Remove Physicians Remove Prescription
article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks.

article thumbnail

Five ways COVID-19 has changed healthcare provision and what it means for pharmas

Clarivate

2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. Three in five physicians in the United States (60%) report having conducted virtual consultations, as do 35% of patients. physicians; Source: Clarivate, Taking the Pulse(R) U.S.

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness. Prescription refill and renewal.

article thumbnail

Handling Economic Uncertainty: The Focus Pharma Marketers Need

Eversana Intouch

Let’s talk about the current economic uncertainty and what it means for pharma marketers. Biopharma valuations are down, especially for public and earlier-stage companies. What does this mean for pharma marketers? What’s the current situation? Pharmaceutical marketing: Increased utilization of financial support services.

article thumbnail

Handling Economic Uncertainy: The Focus Pharma Marketers Need

Eversana Intouch

Let’s talk about the current economic uncertainty and what it means for pharma marketers. Biopharma valuations are down, especially for public and earlier-stage companies. What does this mean for pharma marketers? What’s the current situation? Pharmaceutical marketing: Increased utilization of financial support services.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization. With 27.5% exclusions exist for orphan drug designation and biosimilar competition ).

article thumbnail

Powering pharma’s commercial teams with market access insights

pharmaphorum

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.